

Embargoed: 0700hrs, 11 October,2006

**Akers Biosciences, Inc.**  
("Akers" or the "Company")

**Akers Biosciences Receives U.S. Department of Transportation Clearance to  
Market its Rapid Alcohol Breathalyzers**

Thorofare, NJ, USA—11 October, 2006--Akers Biosciences Inc. (LSE:AKR) is pleased to announce today that it has received market clearance from the National Highway Traffic Safety Administration of the United States Department of Transportation ("DOT") for its new Breath Alcohol Check .02 Detection System.

The DOT approval announced today will allow the Company to address a new \$40 million government requirement for alcohol breathalyzers in the maritime safety industry, as estimated by the US Coast Guard. The Company believes that its products are highly suitable for this industry because of advantages in ease-of-use and product stability under maritime conditions. The Company will now also be able to target its products to all other sectors of the US transportation industry.

Following this approval, the company's products will be distributed by Quest Diagnostics, Inc. and the company's network of distributors. The Company believes that the DOT approval will positively impact the pursuit of sales in other market sectors, including law enforcement, employee screening, personal use, and the educational system.

The Company's breathalyzers provide reliable indicators of alcohol present in a person's breath, which is, in turn, related to a person's blood alcohol level. The single-use devices are portable and low-cost. In a new strategy, the Company has enhanced the technology through the development of small electronic readers. The Company believes that this new product positioning will improve both market penetration and product margins. The Company is the only manufacturer of portable alcohol breathalyzers in the United States.

**Dr. Ray Akers, CEO of Akers Biosciences said,** "We are delighted to be able to announce this market clearance today. This is a significant milestone in the expansion of our breathalyzer business. We believe that this approval will produce revenues in 2006."

**For further information, please contact,**

Dr. Ray Akers	Chief Executive Officer, Akers Biosciences, Inc.	020 7917 9476
Paul Freedman	Chief Financial Officer, Akers Biosciences, Inc.	001 856 848 8698

Ben Simons	Hansard Communications	020 7245 1100
------------	------------------------	---------------

**Akers Biosciences**

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at [www.akersbiosciences.com](http://www.akersbiosciences.com).